Xming Therapeutics, a biotech firm dedicated to the development of generative antibody drugs, has announced the successful closure of a Series A funding round, raising tens of millions in US dollars. This funding initiative was co-led by 5Y Capital and Qiming Venture Partners, with ongoing support from existing shareholder Niuerli Capital and contributions from entities such as Agentic Ventures. The capital raised will be allocated towards progressing ongoing drug development pipelines to pivotal clinical stages, establishing a dry-wet closed-loop AI platform for antibody design, and fostering new partnerships.

Established in 2023, Xming Therapeutics has forged an innovative path by merging AI technology with high-throughput digital biotechnology. This synergy has endowed the company with unique capabilities in antibody discovery and optimization. Presently, Xming Therapeutics has forged strategic alliances with several European and American pharmaceutical giants, propelled multiple self-developed drug candidates forward, and garnered commercial revenues in the tens of millions of US dollars within the past two years.

Dr. Weian Zhao, the visionary founder of Xming Therapeutics, has articulated a grand ambition: to craft a global paradigm for antibody design that is not only perpetually evolving but also imbued with proactive creativity. This forward-thinking approach has garnered widespread optimism among investors, who are buoyed by the company's technological prowess and promising market outlook.